Centrix to launch dual decongestant and cough suppressant in US
This article was originally published in Scrip
Centrix Pharmaceutical plans to launch Clofera (chlophedianol HCl/ pseudoephedrine HCl) for the temporary relief of cough and nasal congestion due to common colds, hay fever or other upper respiratory allergies, in the US by the end of September.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.